Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Scobioala, S; Parfitt, R; Matulat, P; Byrne, J; Langer, T; Troschel, FM; Hesping, AE; Clemens, E; Kaatsch, P; Grabow, D; Kaiser, M; Spix, C; Kremer, LC; Calaminus, G; Baust, K; Kuehni, CE; Weiss, A; Strebel, S; Kuonen, R; Elsner, S; Haupt, R; Garre, ML; Gruhn, B; Kepak, T; Kepakova, K; Winther, JF; Kenborg, L; Rechnitzer, C; Hasle, H; Kruseova, J; Luks, A; Lackner, H; Bielack, S; Beck, JD; Jurgens, H; van den Heuvel-eibrink, MM; Zolk, O; Eich, HT; Zehnhoff-Dinnesen, AA; PanCareLIFE Consortium.
The impact of the temporal sequence of cranial radiotherapy and platin-based chemotherapy on hearing impairment in pediatric and adolescent CNS and head-and-neck cancer patients: A report from the PanCareLIFE consortium
INT J CANCER. 2023; Doi: 10.1002/ijc.34732
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Lackner Herwig
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The impact of the temporal sequence by which cranial radiotherapy (CRT) and platin-based chemotherapy (PCth) are administered on sensorineural hearing loss (SNHL) in pediatric and adolescent central nervous system (CNS) and head-and-neck (HN) cancer patients has not yet been studied in detail. We examined the ototoxic effects of sequentially applied CRT and PCth. This study included children and adolescents with CNS and HN tumors who participated in the multicountry PanCareLIFE (PCL) consortium. Audiological outcomes were compared between patients who received CRT prior to PCth and those who received it afterwards. The incidence, degree and posttreatment progression of SNHL, defined as Muenster classification grade?=MS2b, were evaluated in 141 patients. One hundred and nineteen patients were included in a time-to-onset analysis. Eighty-eight patients received CRT prior to PCth (Group 1) and 53 patients received PCth before CRT (Group 2). Over a median follow-up time of 1.6?years, 72.7% of patients in Group 1 experienced SNHL = MS2b compared to 33.9% in Group 2 (P?
Find related publications in this database (Keywords): cranial radiotherapy; PanCareLIFE project; platin-based chemotherapy; posttreatment hearing loss; therapy sequence